MPN10 Tracker
Help patients monitor symptoms with the MPN10 tracker.
What are you looking for?
top
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
This website is intended for healthcare professionals. Please do not direct patients to this page.
MPN 10: A validated tool to help patients track their myeloproliferative neoplasm (MPN) symptoms
It is important patients living with MPNs (such as myelofibrosis, polycythaemia and essential thrombocythaemia) know how to track their symptoms, as this will help them manage their disease. Validated tools such as MPN 10 can help them record and identify any changes in their health and guide conversations you have with them in the clinic.
Watch a nurse and two patients discuss the importance of tracking symptoms
Click play to watch two patients discuss their symptoms with a consultant nurse specialist and the advantages of using the validated tool, MPN 10, to monitor them.
VIDEO
To learn more about MPN 10, click here
MPN, myeloproliferative neoplasm.
Reference
JAKAVI® (ruxolitinib) Summary of Product Characteristics.
UK | November 2025 | FA-11531983
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.